TITLE

Molecular Analysis of Respiratory Syncytial Virus Reinfections in Infants from Coastal Kenya

AUTHOR(S)
Scott, Paul D.; Ochola, Rachel; Ngama, Mwanajuma; Okiro, Emelda A.; James Nokes, D.; Medley, Graham F.; Cane, Patricia A.
PUB. DATE
January 2006
SOURCE
Journal of Infectious Diseases;1/1/2006, Vol. 193 Issue 1, p59
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background. Individuals are reinfected with respiratory syncytial virus (RSV) repeatedly. The nature of reinfection, in relation to RSV genetic and antigenic diversity, is ill defined and has implications for persistence and vaccine control. Methods. We examined the molecular relatedness of RSV causing primary and repeat infections, by phylogenetic analysis of the attachment (G) gene in 12 infants from a birth cohort in rural Kenya, using nasal wash samples collected during a 16-month period in 2002-2003, which spanned 2 successive epidemics. Results. Six infants were infected during both epidemics, 4 with RSV-A in the first epidemic followed by RSV- B during the second epidemic and 2 with RSV-A during both epidemics, with no significant G gene sequence variability between samples. Two infants were infected and reinfected with different RSV-A strains during the same epidemic. Possible viral persistence was suspected in the remaining 4 infants, although reinfection with the same variant cannot be excluded. Conclusions. These are the first data that specifically address strain-specific reinfections in infancy in relation to the primary infecting variant. The data strongly suggest that, following primary infection, some infants lose strain-specific immunity within 7-9 months (between epidemics) and group-specific immunity within 2-4 months (during an epidemic period).
ACCESSION #
19262259

 

Related Articles

  • An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)- associated acute lower respiratory infections in children. Nair, Harish; Verma, Vasundhara R.; Theodoratou, Evropi; Zgaga, Lina; Huda, Tanvir; Simões, Eric A. F.; Wright, Peter F.; Rudan, Igor; Campbell, Harry // BMC Public Health;2011 Supplement 3, Vol. 11 Issue Suppl 3, p1 

    Background: Respiratory Syncytial Virus (RSV) is the leading cause of acute lower respiratory infections (ALRI) in children. It is estimated to cause approximately 33.8 million new episodes of ALRI in children annually, 96% of these occurring in developing countries. It is also estimated to...

  • Two-Year Periodicity of Respiratory Syncytial Virus Epidemics in Switzerland. Duppenthaler, A.; Gorgievski-Hrisoho, M.; Frey, U.; Aebi, C. // Infection;Mar2003, Vol. 31 Issue 2, p75 

    Background: The annual respiratory syncytial virus (RSV) epidemics vary in time and severity. The aims of this study were (1) to describe the time-related pattern of RSV epidemics in Switzerland and (2) to deduce the most effective time period for administration of prophylactic measures to...

  • Evaluating vaccination strategies for reducing infant respiratory syncytial virus infection in low-income settings. Poletti, Piero; Merler, Stefano; Ajelli, Marco; Manfredi, Piero; Munywoki, Patrick K.; Nokes, D. James; Melegaro, Alessia // BMC Medicine;2015, Vol. 13 Issue 1, p1 

    Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract disease and related hospitalization of young children in least developed countries. Individuals are repeatedly infected, but it is the first exposure, often in early infancy, that results in the vast...

  • PERSPECTIVAS DE DESARROLLO DE UNA VACUNA CONTRA EL VIRUS SINCICIAL RESPIRATORIO. F. Wright, Peter // Vacunas: Prevención de enfermedades y protección de la salud;2004, p182 

    It has been demonstrated that the RSV has a considerable effect in the developing countries and in the industrialized world. Most of them affect the healthy children. It is considered that the intranasal vaccines of live viruses keep on being the most promising method of prevention. There are...

  • Respiratory syncytial virus: pervasive yet evasive.  // CMAJ: Canadian Medical Association Journal;1/20/2004, Vol. 170 Issue 2, p191 

    Provides information on respiratory syncytial virus (RSV). Background and epidemiology of RSV; Clinical management and prevention of RSV.

  • A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation. Turti, Tatyana V.; Baibarina, Elena N.; Degtiareva, Elena A.; Keshishyan, Elena S.; Lobzin, Yurii V.; Namazova-¶aranova, Leyla S.; Prodeus, Andrey P.; Gudkov, Konstantin M.; Kruglova, Anna I.; Schulz, Gregory A.; Notario, Gerard F. // BMC Research Notes;2012, Vol. 5 Issue 1, p484 

    Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LRTIs) in children globally. Predisposing conditions for the development of serious RSV disease include preterm infants and those with cardiopulmonary illness, including congenital heart...

  • Patterns in respiratory synctial virus epidemiology remain stable.  // Infectious Diseases in Children;Apr2010, Vol. 23 Issue 4, p40 

    This article reports on a study on the prevalence of respiratory syncytial viruses in the U.S. from July 2008 to June 2009.

  • Respiratory Syncytial Virus Activity--United States, 2000-01 Season.  // MMWR: Morbidity & Mortality Weekly Report;1/18/2002, Vol. 51 Issue 2, p26 

    Summarizes trends in respiratory syncytial virus (RSV) reported to the United States National Respiratory and Enteric Virus Surveillance System during the 2000-2001 season. Complications of RSV; Dates of regional RSV outbreaks and onsets; Number of laboratories that reported the virus.

  • Exogenous, TAP-independent lysosomal presentation of a respiratory syncytial virus CTL epitope. Johnstone, Carolina; Ramos, Manuel; García-Barreno, Blanca; López, Daniel; Melero, José A; Del Val, Margarita // Immunology & Cell Biology;Nov/Dec2012, Vol. 90 Issue 10, p978 

    Respiratory syncytial virus causes lower respiratory tract infections in infancy and old age, affecting also immunocompromised patients. The viral fusion protein is an important vaccine candidate eliciting antibody and cell-mediated immune responses. CD8+ cytotoxic T lymphocytes (CTLs) are known...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics